C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) reported 2025 results and program progress on Feb 26, 2026. Key items: cemsidomide moved into a Phase 2 MOMENTUM trial with first patient dosed and a recommended Phase 2 dose of 100 µg. Cash, cash equivalents and marketable securities were $297.1M at Dec 31, 2025, providing runway to the end of 2028. Company raised $125M in October 2025 and earned a $2M Biogen milestone; Phase 1b combo trial with elranatamab is on track for Q2 2026.

Positive

• First patient dosed in Phase 2 MOMENTUM (Feb 2026)
• Cash balance $297.1M as of Dec 31, 2025; runway to end of 2028
• $125M gross raised in Oct 2025 equity offering
• $2M milestone earned from Biogen for BIIB145 clinical delivery

Negative

• Net loss $105.0M for full year 2025
• R&D spend $104.2M in 2025 despite program prioritization
• Outstanding warrants could increase dilution if exercised (up to $225M additional proceeds)

News Market Reaction – CCCC

+0.36%

7 alerts

+0.36% News Effect

+3.4% Peak Tracked

-10.0% Trough Tracked

+$1M Valuation Impact

$291M Market Cap

0.7x Rel. Volume

On the day this news was published, CCCC gained 0.36%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.4% during that session. Argus tracked a trough of -10.0% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $291M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q4 2025 Revenue: $11.0 million FY 2025 Revenue: $35.9 million Q4 2025 R&D Expense: $25.0 million +5 more

8 metrics

Q4 2025 Revenue $11.0 million Fourth quarter 2025 vs $5.2 million prior-year quarter

FY 2025 Revenue $35.9 million Full year 2025 vs $35.6 million in 2024

Q4 2025 R&D Expense $25.0 million Fourth quarter 2025 vs $32.5 million prior-year quarter

Q4 2025 Net Loss $20.5 million Fourth quarter 2025 vs $34.6 million prior-year quarter

Q4 2025 EPS $0.18 loss per share Fourth quarter 2025 vs $0.49 loss per share prior-year quarter

Cash & Securities $297.1 million Balance as of December 31, 2025; guidance to fund operations to end of 2028

Equity Offering Proceeds $125 million Gross proceeds from October 2025 underwritten offering

MOMENTUM Trial Size Approximately 100 patients Phase 2 cemsidomide + dexamethasone trial in 4L+ multiple myeloma

Market Reality Check

Price: $2.70 Vol: Volume 6,523,877 is 4.13x...

high vol

$2.70 Last Close

Volume Volume 6,523,877 is 4.13x the 20-day average of 1,581,005, indicating elevated trading interest ahead of and after the earnings release. high

Technical Shares at $2.77 are trading above the 200-day MA of $2.17 and sit 24.11% below the 52-week high and 155.3% above the 52-week low.

Peers on Argus

CCCC gained 15.9%, while several biotech peers (ELTX, IPHA, NTHI, TRDA) show sma...

1 Up

CCCC gained 15.9%, while several biotech peers (ELTX, IPHA, NTHI, TRDA) show smaller single-digit gains and SLS is down. The momentum scanner flagged only SLS, and did not identify a coordinated sector move, suggesting today’s reaction is primarily stock-specific to C4’s earnings and pipeline update.

Common Catalyst One peer, TRDA, also reported earnings, but there is no confirmed sector-wide price reaction.

Previous Earnings Reports

5 past events · Latest: Nov 06 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 06	Q3 2025 earnings	Positive	+0.4%	Equity raise extended runway and positive cemsidomide Phase 1 efficacy data.
Aug 07	Q2 2025 earnings	Positive	+31.6%	Promising cemsidomide ORR data and maintained cash position despite lower revenue.
May 07	Q1 2025 earnings	Positive	+6.4%	Strong multiple myeloma responses and reduced net loss with solid cash runway.
Feb 27	FY 2024 earnings	Positive	-1.9%	Improved revenue and narrowed net loss but shares slipped modestly afterward.
Oct 31	Q3 2024 earnings	Positive	-3.6%	Higher revenue and solid cash yet stock traded lower post-update.

Pattern Detected

Earnings updates have generally been received positively, with most events showing share price gains and a minority of instances where stock performance diverged from constructive operational/financial progress.

Recent Company History

Over the past five earnings cycles, C4 Therapeutics has consistently highlighted progress for cemsidomide and maintained a solid cash runway. Events on Aug 7, 2025 and Nov 6, 2025 paired clinical updates with strengthened liquidity, while the Feb 27, 2025 and Oct 31, 2024 reports emphasized growing revenue and narrowing losses. Price reactions have been mostly positive, with three earnings events posting gains and two showing mild declines despite constructive fundamentals. Today’s 2025 year-end results continue this pattern of clinical and financial de-risking.

Historical Comparison

+6.6% avg move · In the past five earnings reports, CCCC’s average move was 6.58%. Today’s 15.9% gain on 2025 results...

earnings

+6.6%

Average Historical Move earnings

In the past five earnings reports, CCCC’s average move was 6.58%. Today’s 15.9% gain on 2025 results is notably larger than typical, indicating a stronger-than-usual market response to the combination of later-stage cemsidomide plans and extended cash runway.

Across recent earnings, C4 Therapeutics has moved cemsidomide from early Phase 1 data toward registrational strategies, while steadily extending cash runway from 2027 into the end of 2028 and refining its broader degrader pipeline.

Regulatory & Risk Context

Active S-3 Shelf · $400,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-21

$400,000,000 registered capacity

An effective S-3 shelf filed on Nov 21, 2025 allows C4 Therapeutics to offer up to $400,000,000 of various securities, including up to $125,000,000 of common stock via an at-the-market program. The shelf is currently marked as not effective in the context and has 0 recorded usages, but it provides flexibility for future capital raises that could impact existing shareholders if utilized.

Market Pulse Summary

This announcement combines 2025 financial results with meaningful pipeline milestones, including pro...

Analysis

This announcement combines 2025 financial results with meaningful pipeline milestones, including progression of cemsidomide into a Phase 2 MOMENTUM trial and plans for a Phase 1b combination study. Revenue reached $35.9M with reduced R&D and G&A expenses, and year-end cash of $297.1M is expected to fund operations through 2028. Investors may track execution against trial timelines, future business development milestones, and any use of the $400M shelf registration when assessing ongoing risk and opportunity.

Key Terms

accelerated approval, phase 2, phase 1b, multiple myeloma, +4 more

8 terms

accelerated approval regulatory

"The MOMENTUM trial was designed for potential accelerated approval with a recommended..."

Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

phase 2 medical

"the first patient was dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

phase 1b medical

"Phase 1b trial of cemsidomide in combination with elranatamab in earlier lines..."

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

multiple myeloma medical

"MOMENTUM trial for Multiple Myeloma in the Fourth Line or Later..."

A cancer of the blood that starts in plasma cells, the immune system’s antibody-producing cells in bone marrow. It behaves like a factory where the workers go rogue, crowding out healthy cells and causing bone damage, anemia and infections; treatments and trial results can sharply affect drug sales, regulatory approvals and company valuations, so progress or setbacks are closely watched by investors.

egfr l858r medical

"CFT8919: EGFR L858R Degrader for Non-Small-Cell Lung Cancer (NSCLC)..."

EGFR L858R is a specific change in the EGFR gene that alters a single building block of the protein, comparable to a light switch getting stuck in the “on” position and driving uncontrolled cell growth. It matters to investors because this mutation predicts whether certain targeted cancer drugs and companion diagnostic tests will work for a patient, influencing the potential market size, regulatory approvals, and revenue prospects for therapies and diagnostics.

non-small-cell lung cancer medical

"EGFR L858R Degrader for Non-Small-Cell Lung Cancer (NSCLC)..."

A common type of lung cancer that starts when normal cells in the lungs grow out of control and form tumors; it differs from the less common “small cell” form in how it behaves and is treated. It matters to investors because test results, drug approvals, and new diagnostics for this disease can rapidly change the commercial outlook for companies working on treatments, much like a new product shaping demand in a large market.

btk degrader medical

"BIIB145, a BTK degrader, designed by C4T and delivered to Biogen..."

A BTK degrader is a type of drug designed to attach to Bruton’s tyrosine kinase (BTK) — a protein that helps certain immune and cancer cells survive — and mark it for removal by the cell’s disposal system. For investors, BTK degraders matter because they can potentially work when older BTK-blocking drugs fail, may reduce long-term side effects, and could expand or shift market opportunities in cancer and autoimmune treatments.

bispecific antibody medical

"elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody..."

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

AI-generated analysis. Not financial advice.

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later

Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy

Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases

Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025

WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the year ended December 31, 2025, as well as business updates.

“We made significant progress in 2025, notably demonstrating cemsidomide’s best-in-class potential, establishing an efficient and differentiated regulatory path for cemsidomide, and extending our cash runway beyond key value‑inflection milestones, further positioning us to become a fully integrated biopharmaceutical company,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “As cemsidomide progresses into later-stage clinical trials across multiple lines of therapy in multiple myeloma, we believe it is well positioned to become the IKZF1/3 degrader of choice. We continue to advance our discovery strategy, focused on targets that have a strong degrader rationale with first-in-class potential in inflammation, neuroinflammation and neurodegeneration diseases. Together, these achievements will bring us closer to delivering transformative TPD medicines for patients with significant unmet needs.”

FOURTH QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS

• In February 2026, the first patient was dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone in the fourth line or later MM setting. The MOMENTUM trial was designed for potential accelerated approval with a recommended Phase 2 dose of 100 µg. The trial will enroll approximately 100 patients with enrollment expected to be completed in Q1 2027.
  
• In October 2025, C4T entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO^®), a B-cell maturation antigen CD3 targeted bispecific antibody, for the upcoming Phase 1b trial of cemsidomide in combination with elranatamab in earlier lines of MM treatment. C4T has continued to execute operational steps necessary for the initiation of the Phase 1b trial, which is expected in Q2 2026.
  
• In October 2025, C4T raised $125 million in gross proceeds through an underwritten offering with the potential to earn up to $225 million in additional proceeds if the outstanding warrants are exercised.
  
• In January 2026, C4T earned a $2 million milestone payment from Biogen related to BIIB145, a BTK degrader, designed by C4T and delivered to Biogen for clinical development. This is the second degrader that Biogen has advanced into the clinic under the Biogen and C4T collaboration.
  

KEY UPCOMING MILESTONES

Cemsidomide: IKZF1/3 Degrader for Relapsed Refractory Multiple Myeloma (RRMM)

• On track to initiate the Phase 1b trial of cemsidomide in combination with elranatamab in Q2 2026 with plans to provide incremental progress throughout 2026.
  
• Present further analysis of the data from the completed Phase 1 trial of cemsidomide in combination with dexamethasone in mid-2026.
  
• Share the plan to initiate an additional Phase 1b trial to evaluate cemsidomide in combination with other anti-myeloma agents in mid-2026.
  

CFT8919: EGFR L858R Degrader for Non-Small-Cell Lung Cancer (NSCLC)

• By end of Q1 2026, utilize data from the Phase 1 dose escalation trial conducted by Betta Pharmaceuticals to inform potential ex-China clinical development.
  

Research & Discovery: Internal Discovery Efforts Focused on Inflammation, Neuroinflammation & Neurodegeneration (INN) with Collaboration Efforts Focused on Oncology & Non-oncology

• Optimize indication selection for multiple targets across discovery portfolio focused on INN in 2026.
  
• Deliver at least one development candidate to a collaboration partner by year-end 2026.
  
• Advance existing collaborations toward key milestones by year-end 2026.
  

UPCOMING INVESTOR EVENTS

• March 3, 2026, at 11:50 AM ET: Management will participate in a presentation and fireside chat at the TD Cowen 46th Annual Health Care Conference taking place in Boston, Massachusetts.
  
• March 10, 2026, at 8:00 AM ET: Management will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference taking place in Miami, Florida.
  

FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Revenue: Total revenue for the fourth quarter and full year ended December 31, 2025, was $11.0 million and $35.9 million, respectively, compared to $5.2 million and $35.6 million for the prior year periods. The increase in revenue for the fourth quarter of 2025, as compared to the prior year period, reflects the prioritization of one KRAS project under the collaboration with Merck KGaA, Darmstadt, Germany.

Research and Development (R&D) Expense: R&D expense for the fourth quarter and full year ended December 31, 2025, was $25.0 million and $104.2 million, respectively, compared to $32.5 million and $110.6 million for the prior year periods. The decrease in R&D expense for the fourth quarter of 2025, as compared to the prior year period, was primarily related to the completion of the CFT1946 Phase 1 clinical trial.

General and Administrative (G&A) Expense: G&A expense for the fourth quarter and full year ended December 31, 2025, was $9.2 million and $36.2 million, respectively, compared to $10.4 million and $42.1 million for the prior year periods. The decrease in G&A expense for the fourth quarter of 2025, as compared to the prior year period, was primarily related to lower stock-based compensation expense.

Net Loss and Net Loss per Share: Net loss for the fourth quarter and full year ended December 31, 2025, was $20.5 million and $105.0 million, respectively, compared to $34.6 million and $105.3 million for the prior year periods. Net loss per share for the fourth quarter and full year ended December 31, 2025, was $0.18 and $1.27, respectively, compared to $0.49 and $1.52 for the prior year periods.

Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of December 31, 2025, was $297.1 million, compared to $199.8 million as of September 30, 2025, and $267.3 million as of December 31, 2024. The increase in cash, cash equivalents and marketable securities during 2025 was primarily the result of the net proceeds from the October equity offering partially offset by the cash used to fund operations and advance our programs. The company expects that its current cash, cash equivalents and marketable securities will enable it to fund its operating plan to the end of 2028.

About Cemsidomide
Cemsidomide is an investigational, orally bioavailable molecular glue degrader (MonoDAC^® degrader) of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the Phase 1 trial, which has completed enrollment, show cemsidomide’s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that support the potential for durable outcomes.

About the MOMENTUM Trial
MOMENTUM (Multi-center trial Of cemsidoMidE iN relapsed/refracTory mUltiple Myeloma) is a Phase 2, open-label, single-arm study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Data from the Phase 1 trial identified 100 µg as the recommended Phase 2 dose. The primary endpoint is overall response rate per International Myeloma Working Group response criteria, as assessed by an independent review committee. Approximately 100 patients who have received at least three prior anti-myeloma regimens that must have included an IKZF1/3 degrader, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager or CAR-T therapy will be enrolled in the trial. More information is available at clinicaltrials.gov (NCT07284758).

About Cemsidomide in Combination With Elranatamab (ELREXFIO®)
The Phase 1b trial is designed to evaluate the safety, tolerability and preliminary efficacy of cemsidomide in combination with elranatamab, an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. The study will evaluate different cemsidomide dose levels (beginning with 75 µg, with the opportunity to simultaneously explore 50 µg and 100 µg) in patients who have received one to four prior lines of therapy, which must have consisted of at least one IKZF1/3 degrader. Exclusion criteria for patients include those who have received prior treatment with a BCMA-directed T-cell engager or BCMA-directed CAR-T therapy. More information is available at clinicaltrials.gov (NCT07280013).

About Multiple Myeloma
Multiple myeloma (MM) is a rare blood cancer affecting plasma cells. Approximately 36,000 people in the United States are diagnosed with MM each year. Approved IKZF1/3 degraders remain foundational therapies across lines of MM treatment. Despite advances, including immune-directed approaches, most patients ultimately relapse, underscoring a growing need for new therapeutics options that continue to leverage IKZF1/3 degradation to drive myeloma cell death and T-cell activation.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Forward Looking Statements
This press release contains “forward-looking statements” of C4 Therapeutics, Inc., within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO^® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC^® degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement and patient enrollment; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to replicate interim or early-stage results from our clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials; regulatory developments in the United States and foreign countries; the anticipated timing and content of presentations of data from our clinical trials; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.

Contacts:
Investors: 
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com

Media: 
Loraine Spreen 
Senior Director, Corporate Communications & Patient Advocacy 
LSpreen@c4therapeutics.com

Condensed Consolidated Balance Sheet Data (in thousands)
	December 31, 2025				December 31, 2024
Cash, cash equivalents and marketable securities	$	297,100			$	267,263
Total assets		359,075				349,602
Deferred revenue		28,334				47,169
Total stockholders' equity		256,587				215,986

Condensed Consolidated Statements of Operations  (in thousands, except share and per share amounts)
	Three Months Ended December 31,								Years Ended December 31,
	2025				2024				2025				2024
Revenue from collaboration agreements	$	11,016			$	5,177			$	35,947			$	35,584
Operating expenses:
Research and development		24,982				32,513				104,240				110,637
General and administrative		9,179				10,373				36,196				42,124
Impairment of long-lived assets		—				—				10,733				—
Restructuring		—				—				—				2,437
Total operating expenses		34,161				42,886				151,169				155,198
Loss from operations		(23,145	)			(37,709	)			(115,222	)			(119,614	)
Other income, net:
Interest and other income, net		2,780				3,267				10,349				14,429
Total other income, net		2,780				3,267				10,349				14,429
Loss before income taxes		(20,365	)			(34,442	)			(104,873	)			(105,185	)
Income tax expense		(121	)			(131	)			(121	)			(131	)
Net loss	$	(20,486	)		$	(34,573	)		$	(104,994	)		$	(105,316	)
Net loss per share − basic and diluted	$	(0.18	)		$	(0.49	)		$	(1.27	)		$	(1.52	)
Weighted-average shares outstanding − basic and diluted		116,784,306				70,606,156				82,894,459				69,372,993

FAQ

What did C4 Therapeutics (CCCC) report about cemsidomide on February 26, 2026?

C4 reported cemsidomide entered a Phase 2 MOMENTUM trial with first patient dosed in Feb 2026. According to the company, the trial uses a recommended Phase 2 dose of 100 µg, will enroll ~100 patients and targets potential accelerated approval.

How much cash did C4 Therapeutics (CCCC) have at December 31, 2025 and how long is the runway?

C4 reported $297.1 million in cash, cash equivalents and marketable securities as of Dec 31, 2025. According to the company, this balance is expected to fund its operating plan through the end of 2028.

When is the Phase 1b trial of cemsidomide with elranatamab (CCCC) expected to start?

C4 said the Phase 1b trial combining cemsidomide and elranatamab is on track to initiate in Q2 2026. According to the company, Pfizer will supply elranatamab under a clinical collaboration and supply agreement.

What were C4 Therapeutics' (CCCC) full year 2025 financial highlights for revenue and net loss?

C4 reported full year 2025 revenue of $35.9 million and a net loss of $105.0 million. According to the company, revenue rose slightly from 2024 while net loss remained similar year-over-year.

Did C4 Therapeutics (CCCC) receive any collaboration milestone payments in early 2026?

Yes, C4 reported earning a $2 million milestone payment from Biogen in January 2026. According to the company, the payment related to BIIB145, a BTK degrader designed by C4 and delivered for clinical development.